{"id":"NCT01986101","sponsor":"Sumitomo Pharma Co., Ltd.","briefTitle":"A Phase III Study of SM-13496 in Patients With Bipolar I Depression.","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-19","primaryCompletion":"2017-02-01","completion":"2017-02-16","firstPosted":"2013-11-18","resultsPosted":"2019-07-25","lastUpdate":"2022-04-12"},"enrollment":525,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Depression"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"SM-13496","otherNames":["Lurasidone HCl"]},{"type":"DRUG","name":"SM-13496","otherNames":["Lurasidone HCl"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"SM-13496 20 - 60 mg/day","type":"EXPERIMENTAL"},{"label":"SM-13496 80 - 120 mg/day","type":"EXPERIMENTAL"}],"summary":"The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6","timeFrame":"Baseline to 6 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-10.6,"sd":0.72},{"arm":"SM-13496 20 - 60 mg/Day","deltaMin":-13.6,"sd":0.69},{"arm":"SM-13496 80 - 120 mg/Day","deltaMin":-12.6,"sd":0.73}],"pValues":[{"comp":"OG000 vs OG001","p":"0.007"},{"comp":"OG000 vs OG002","p":"0.057"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":8,"countries":["Japan","Lithuania","Malaysia","Philippines","Russia","Slovakia","Taiwan","Ukraine"]},"refs":{"pmids":["32827348","39098761","36632763","32902200"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":172},"commonTop":["Akathisia","Nausea","Headache","Somnolence","Nasopharyngitis"]}}